- Previous Close
1,897.00 - Open
1,880.00 - Bid 1,920.00 x --
- Ask 1,930.00 x --
- Day's Range
1,878.00 - 1,920.00 - 52 Week Range
1,823.00 - 2,790.00 - Volume
175,670 - Avg. Volume
123,712 - Market Cap (intraday)
351.153B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs. Yungjin Pharm. Co., Ltd. was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
www.yungjin.co.kr574
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 003520.KS
View MorePerformance Overview: 003520.KS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 003520.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 003520.KS
View MoreValuation Measures
Market Cap
351.15B
Enterprise Value
412.80B
Trailing P/E
274.29
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.34
Price/Book (mrq)
3.91
Enterprise Value/Revenue
1.64
Enterprise Value/EBITDA
24.46
Financial Highlights
Profitability and Income Statement
Profit Margin
5.37%
Return on Assets (ttm)
3.63%
Return on Equity (ttm)
9.00%
Revenue (ttm)
158.79B
Net Income Avi to Common (ttm)
8.53B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
4.61B
Total Debt/Equity (mrq)
28.30%
Levered Free Cash Flow (ttm)
-1.3B